Disruptive Tech Research
  • About
  • Media
  • Research
  • Subscribe
  • Log in
Select Page

Q2 2022 Portfolio Review & Outlook

by Lou Basenese | Jun 15, 2022 | Webinar

A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.

ATOM: Lands Another “Major” Foundry Customer, Plus 10 Takeaways From Q1 Report

ATOM: Lands Another “Major” Foundry Customer, Plus 10 Takeaways From Q1 Report

by Lou Basenese | May 2, 2022 | ATOM

Key takeaways from the latest quarterly report from Atomera Inc. (ATOM), including the possible identity of the latest “major” foundry customer…

[IMNM] Biotech Absurdity

[IMNM] Biotech Absurdity

by Lou Basenese | Apr 27, 2022 | IMNM

Low float stocks are prone to major moves on nominal volume. Unfortunately in both directions. Here’s what’s going on with IMNM…

[Video] Cue Biopharma Q&A Session With Dr. D.J. Verret

by Lou Basenese | Feb 21, 2022 | CUE

In this 1.5 hour webinar, Dr. D.J. Verret shares his unique clinical perspective on Cue Biopharma’s (CUE) approach and latest data

[Video] ATOM: 5 Key Takeaways From The Q4 2021 Report

by Lou Basenese | Feb 16, 2022 | ATOM

Per your feedback, here’s my quick take on Atomera’s fourth quarter report…

RESN: Time To Lock In Our 5G Gains

RESN: Time To Lock In Our 5G Gains

by Lou Basenese | Feb 15, 2022 | RESN

Resonant Inc. (RESN) announced it’s being acquired for $4.50 per share by long-term strategic partner, Murata

[CUE] “That Data Is Amazing!” So Why Is The Stock Down?

[CUE] “That Data Is Amazing!” So Why Is The Stock Down?

by Lou Basenese | Jan 27, 2022 | CUE

Here’s a full rundown on the important takeaways from CUE’s conference call and my thoughts on the recent trading activity…

[Video] What To Expect From CUE This Afternoon

[Video] What To Expect From CUE This Afternoon

by Lou Basenese | Jan 26, 2022 | CUE

Like expectant parents, everyone’s wondering what will be revealed on today’s update call. Here are my reasonable expectations…

DTR: Year-End 2021 Portfolio Review & 2022 Outlook (Part 2)

by Lou Basenese | Jan 20, 2022 | Webinar

A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.

DTR: Year-End 2021 Portfolio Review & 2022 Outlook (Part 1)

by Lou Basenese | Jan 11, 2022 | Webinar

A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.

« Older Entries

Your account

Sign in

Research Links

  • Real-Time Blog
  • Active Recs
  • Archive

Recent Posts

  • Q2 2022 Portfolio Review & Outlook
  • ATOM: Lands Another “Major” Foundry Customer, Plus 10 Takeaways From Q1 Report
  • [IMNM] Biotech Absurdity
  • [Video] Cue Biopharma Q&A Session With Dr. D.J. Verret
  • [Video] ATOM: 5 Key Takeaways From The Q4 2021 Report
  • RESN: Time To Lock In Our 5G Gains
  • [CUE] “That Data Is Amazing!” So Why Is The Stock Down?